Biohaven Ltd. (NYSE:BHVN) Receives $25.57 Average PT from Analysts

Shares of Biohaven Ltd. (NYSE:BHVN) have received an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $25.5714.

BHVN has been the subject of a number of analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Biohaven in a research report on Monday, December 29th. HC Wainwright reaffirmed a “neutral” rating and issued a $11.00 price objective on shares of Biohaven in a research note on Friday, December 26th. Bank of America cut shares of Biohaven from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a research report on Wednesday, November 5th. Finally, William Blair restated a “market perform” rating on shares of Biohaven in a report on Friday, December 26th.

Biohaven Stock Performance

Shares of NYSE BHVN opened at $11.75 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 1.91. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -1.55 and a beta of 1.14. The stock’s fifty day simple moving average is $11.09 and its 200 day simple moving average is $13.10. Biohaven has a 52-week low of $7.48 and a 52-week high of $44.28.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, November 10th. The company reported ($1.64) EPS for the quarter, beating the consensus estimate of ($1.91) by $0.27. As a group, sell-side analysts forecast that Biohaven will post -8.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Biohaven news, CAO George C. Clark acquired 17,000 shares of Biohaven stock in a transaction that occurred on Monday, November 17th. The stock was purchased at an average cost of $8.52 per share, with a total value of $144,840.00. Following the purchase, the chief accounting officer owned 20,000 shares in the company, valued at approximately $170,400. The trade was a 566.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John W. Childs acquired 3,333,333 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were acquired at an average price of $7.50 per share, with a total value of $24,999,997.50. Following the completion of the transaction, the director directly owned 5,653,904 shares in the company, valued at approximately $42,404,280. This trade represents a 143.64% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 4,416,999 shares of company stock valued at $33,144,833 over the last ninety days. Corporate insiders own 14.60% of the company’s stock.

Institutional Investors Weigh In On Biohaven

A number of hedge funds and other institutional investors have recently made changes to their positions in BHVN. PNC Financial Services Group Inc. grew its stake in shares of Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after buying an additional 1,268 shares in the last quarter. PFS Partners LLC bought a new position in Biohaven during the third quarter valued at approximately $60,000. Elkhorn Partners Limited Partnership lifted its stake in Biohaven by 26.1% in the second quarter. Elkhorn Partners Limited Partnership now owns 5,800 shares of the company’s stock valued at $82,000 after acquiring an additional 1,200 shares during the last quarter. Virtus Investment Advisers LLC grew its position in Biohaven by 47.7% in the second quarter. Virtus Investment Advisers LLC now owns 6,032 shares of the company’s stock worth $85,000 after acquiring an additional 1,949 shares in the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Biohaven during the 3rd quarter worth $87,000. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.